Shares in Telix Pharmaceuticals Ltd (ASX: TLX) are expected to attract attention following the company’s announcement that it has met its full-year revenue guidance and experienced significant growth in its fourth-quarter revenue. The drug developer reported a full-year revenue of US$804 million, aligning with its upgraded guidance of US$800 million to US$820 million.
In the fourth quarter, Telix achieved a revenue of US$208 million, marking a remarkable 46% increase compared to the same period last year. The company’s precision medicine division contributed approximately US$161 million to this total, reflecting a 4% increase over the third quarter. This growth was largely driven by the successful launch of Gozellix in the United States, following its reimbursement approval by the Centers for Medicare and Medicaid Services (CMS), effective from October 1, 2025.
Dr. Christian Behrenbruch, managing director of Telix, expressed satisfaction with the results, highlighting that the precision medicine business demonstrated excellent sequential growth in the fourth quarter. He noted, “This revenue growth outpaced a 3% increase in dose volumes, demonstrating the positive impact of our two-product strategy on market share and pricing. With strong early uptake of Gozellix and a robust pipeline of key accounts integrating Gozellix and ARTMS technology, Telix is well-positioned for sustained growth in 2026.”
Advancements in Clinical Trials
On the clinical trial front, Telix announced that the first international patients have been dosed in part two of the ProstACT Global Phase 3 study of TLX591-Tx, aimed at treating advanced prostate cancer. This compound represents Telix’s lead prostate cancer therapy candidate, and the company is preparing for a readout of safety and dosimetry data from part one of the trial.
The study is currently open for enrollment in Australia, New Zealand, and Canada, with additional sites planned for China, Singapore, South Korea, Turkey, the United Kingdom, and Japan, where regulatory approvals have already been granted. Data from part one will be presented to the U.S. Food and Drug Administration (FDA) to determine eligibility for U.S. patients to participate in part two.
Additionally, Telix reported that it has dosed its first patients in the Solace study, which investigates its therapeutic candidate for treating pain in patients with osteoblastic bone metastases from prostate and breast cancers.
New Drug Application Submitted in China
In a significant development, the National Medical Products Administration (NMPA) of China has accepted a new drug application (NDA) for Illuccix, Telix’s lead prostate cancer imaging agent. The NDA was submitted in collaboration with Telix’s strategic partner in the Greater China region, Grand Pharmaceutical Group Limited. The application seeks a broad label that reflects clinical utility across multiple stages of prostate cancer care and includes data from the Illuccix China Pivotal Phase 3 Registration study, which reported positive top-line results in December 2025.
Telix noted that more than 134,000 men were diagnosed with prostate cancer in 2022, with the incidence increasing by approximately 6% annually. Illuccix has already received approval from the FDA in the United States, the Therapeutic Goods Administration in Australia, the Medicines and Healthcare Products Regulatory Agency in the United Kingdom, and in 19 countries within the European Economic Area.
With these achievements, Telix Pharmaceuticals demonstrates a strong trajectory in both revenue growth and clinical advancements, positioning the company for a promising future in the competitive pharmaceutical landscape.
